<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584594</url>
  </required_header>
  <id_info>
    <org_study_id>KARIM-08-PSEPOVA</org_study_id>
    <nct_id>NCT03584594</nct_id>
  </id_info>
  <brief_title>Presepsin in the Diagnosis of Sepsis in Critically Ill Patients</brief_title>
  <official_title>Prepepsin, the Improvement of the Early Inflammatory Biomarkers Strategy for the Diagnostics of Sepsis in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Public Health Institute Ostrava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is one of the most common causes of death worldwide. It is caused by a complex of
      inadequate host responses to infection. Sepsis remains a major challenge of modern intensive
      care medicine. Despite recent improvements, the incidence of sepsis in critically ill
      patients increases steadily (25%) and mortality rates remain unacceptably high (30%). It is
      difficult to distinguish the sepsis from the non-infectious systemic inflammatory response
      syndrome. Early identification of the origin of infection can help dramatically to improve
      outcome and reduce mortality. That is why clinicians need fast, reliable and specific
      biomarkers for sepsis recognition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison between the detection of novel early inflammatory biomarker (PSEP) and the others
      normally used biomarkers (c-reactive protein - CRP, interleukin 6 - IL6, procalcitonin - PCT)
      in the early diagnosing of sepsis in the critically ill patients A broad range of clinical
      and laboratory parameters are combined (Surviving sepsis campaign, international guidelines)
      for early sepsis identification: white blood cells (WBC), C-reactive protein (CRP),
      interleukin 6 (IL-6), procalcitonin (PCT).

      An ideal biomarker should be a fast and specific increase in sepsis, short half-life, rapid
      decrease after administration of an effective therapy and fast (bed-side) method of
      determination. None of the current biomarkers have all of these characteristics.

      We investigate the diagnostic accuracy of presepsin compared to other biomarkers (WBC, PCT,
      IL6, CRP) for infection or sepsis, defined according to Sepsis-3 definition (Singer, JAMA
      2016) in adult patients admitted to ICU with suspected sepsis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum concentration of Presepsin</measure>
    <time_frame>47 months</time_frame>
    <description>Serum concentration of Presepsin in patients with sepsis or septic shock will be compared to PCT, IL6 and CRP results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Receiver-operating characteristic Curve</measure>
    <time_frame>47 months</time_frame>
    <description>Area under the Receiver-operating characteristic Curve (ROC-AUC) of the presepsin and other biomarkers (PCT, IL6, CRP) for diagnostic value of any biomarker will be analysed on a scale 0-100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of serum concentration of presepsin with detection of microbial agents</measure>
    <time_frame>47 months</time_frame>
    <description>Comparison of presepsin concentration in serum with the results of culture/microscopy of a pathogen from a clinical focus using methods of classical microbiology. In patients with risk factors for invasive mycosis, comparison of presepsin concentration with serum for galactomannan (GM) and beta- D- glucan (BG) detection will be performed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sepsis</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Presepsin assessment</arm_group_label>
    <description>Residual blood samples after performing all necessary blood examinations and analyses will be used to determine the level of presepsin, as the potential new biomarker of infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Presepsin measurement</intervention_name>
    <description>Presepsin measurements are performed with PathFast immunoassay analytical system on the ICU, bedside method. (Mitsubishi Chemical, Japan).</description>
    <arm_group_label>Presepsin assessment</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Residual blood samples remaining after performing all necessary standard and indicated blood
      examinations and analyses will be used to determine the level of presepsin, as the potential
      new biomarker of sepsis in critically ill patients.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a minimum 18 years admitted to ICU (surgical, traumatic, medical patients),
        who had proven criteria for sepsis, septic shock.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent

          -  diagnosis of sepsis from qSOFA (quick Subsequent Organ Failures Assessment)

          -  need of vasopressors for mean arterial pressure (MAP) ≥ 65 mmHg

          -  lactate levels ≥ 2mmol/l despite adequate volume resuscitation

        Exclusion Criteria:

          -  age below 18 years

          -  terminal state of disease

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcela Káňová, MD,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ostrava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petr Vávra, Ass.Prof.,MD,Ph.D.</last_name>
    <phone>0042059737</phone>
    <phone_ext>2544</phone_ext>
    <email>petr.vavra@fno.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiří Hynčica</last_name>
    <phone>0042059737</phone>
    <phone_ext>2587</phone_ext>
    <email>jiri.hyncica@fno.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Public Health Institute Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian Region</state>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radim Dobiáš, Mgr.</last_name>
      <phone>0042059620</phone>
      <phone_ext>0239</phone_ext>
      <email>radim.dobias@zuova.cz</email>
    </contact>
    <investigator>
      <last_name>Radim Dobiáš, Mgr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian Region</state>
        <zip>780 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Vávra, Ass.Prof.,MD,Ph.D.</last_name>
      <phone>0042059737</phone>
      <phone_ext>2544</phone_ext>
      <email>petr.vavra@fno.cz</email>
    </contact>
    <contact_backup>
      <last_name>Jiří Hynčica</last_name>
      <phone>0042059737</phone>
      <phone_ext>2587</phone_ext>
      <email>jiri.hyncica@fno.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Marcela Káňová, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.</citation>
    <PMID>26903338</PMID>
  </reference>
  <reference>
    <citation>Masson S, Caironi P, Fanizza C, Thomae R, Bernasconi R, Noto A, Oggioni R, Pasetti GS, Romero M, Tognoni G, Latini R, Gattinoni L. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Med. 2015 Jan;41(1):12-20. doi: 10.1007/s00134-014-3514-2. Epub 2014 Oct 16. Erratum in: Intensive Care Med. 2015 Sep;41(9):1736.</citation>
    <PMID>25319385</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Hu ZD, Song J, Shao J. Diagnostic Value of Presepsin for Sepsis: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015 Nov;94(47):e2158. doi: 10.1097/MD.0000000000002158. Review.</citation>
    <PMID>26632748</PMID>
  </reference>
  <reference>
    <citation>Ackland GL, Prowle JR. Presepsin: solving a soluble (CD14) problem in sepsis? Intensive Care Med. 2015 Feb;41(2):351-3. doi: 10.1007/s00134-014-3642-8. Epub 2015 Jan 22.</citation>
    <PMID>25608923</PMID>
  </reference>
  <reference>
    <citation>Okamura Y. [Usefulness of Presepsin Measurement: A New Biomarker for Sepsis]. Rinsho Byori. 2015 Jan;63(1):62-71. Review. Japanese.</citation>
    <PMID>26524880</PMID>
  </reference>
  <reference>
    <citation>Rogić D, Juroš GF, Petrik J, Vrančić AL. Advances and Pitfalls in Using Laboratory Biomarkers for the Diagnosis and Management of Sepsis. EJIFCC. 2017 May 1;28(2):114-121. eCollection 2017 May.</citation>
    <PMID>28757819</PMID>
  </reference>
  <reference>
    <citation>Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, Nishida T, Irie Y, Miura M, Iguchi H, Fukui Y, Tanaka K, Nojima T, Okamura Y. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012 Dec;18(6):891-7. doi: 10.1007/s10156-012-0435-2. Epub 2012 Jun 13.</citation>
    <PMID>22692596</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>July 12, 2019</last_update_submitted>
  <last_update_submitted_qc>July 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>presepsin</keyword>
  <keyword>biomarkers</keyword>
  <keyword>sepsis</keyword>
  <keyword>diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The investigators have not decided to make individual participant data available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

